XML 65 R48.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaboration and Licensing Agreements - Narrative (Details) $ in Millions, ¥ in Billions | 1 Months Ended | 3 Months Ended | 12 Months Ended | 50 Months Ended | 79 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2019 USD ($) item | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Nov. 30, 2017 USD ($) | Jun. 30, 2015 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 CAD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 JPY (¥) | Feb. 28, 2019 USD ($) | Jan. 01, 2018 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | $ 10,097,000 |  | $ 7,571,000 | $ 5,281,000 |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  |  | 502,000 |  | 0 |  |  |  | $ 502,000 | $ 502,000 |  |  |
Deferred revenue |  |  |  |  |  |  | 0 |  | 4,177,000 |  |  |  | 0 | 0 |  |  |
Cost of revenue |  |  |  |  |  |  | 1,000,000 |  | 145,000 | 600,000 |  |  |  |  |  |  |
AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  |  |  |  |  | 1,000,000 |  | 145,000 | 600,000 | $ 466,000 | $ 9,400,000 |  |  |  |  |
Maximum potential payment per agreement |  |  |  |  |  |  | 75,000,000 |  |  |  |  |  | 75,000,000 | 75,000,000 |  |  |
Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 5,013,000 |  | 706,000 | 4,500,000 |  |  |  |  |  |  |
Product supply revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 907,000 |  | 1,501,000 | 322,000 |  |  |  |  |  |  |
2019 KKC Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 4,200,000 |  | 5,400,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | 0 |  | 4,177,000 | $ 4,541,000 |  |  | 0 | 0 |  |  |
2019 KKC Agreement | Kyowa Kirin Co. Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fees | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First installment of upfront license fees | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of payment of license fee, first installment | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second installment of upfront license fees | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of agreement | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial transaction price | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2019 KKC Agreement | Kyowa Kirin Co. Ltd | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of separate collaborative agreements | item | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2017 KKC Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  |  | 500,000 |  |  |  |  |  | 500,000 | 500,000 |  |  |
Prepayment received |  |  |  |  |  |  | 3,200,000 |  |  |  |  |  |  |  |  |  |
Unbilled prepayments |  |  |  |  |  |  | 1,500,000 |  |  |  |  |  | 1,500,000 | 1,500,000 |  |  |
2017 KKC Agreement | Kyowa Kirin Co. Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fees |  |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Unbilled revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |
Potential development milestones |  |  |  | $ 55,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Potential commercialization milestones |  |  |  |  |  |  | 73,900,000 |  |  |  |  |  | 73,900,000 | 73,900,000 | ¥ 8.5 |  |
2017 KKC Agreement | AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Uncharged license fee reclassified to accounts payable |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |
2017 KKC Agreement | Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 5,000,000 |  | 0 |  |  |  | $ 10,000,000 |  |  |  |
2017 KKC Agreement | Product supply revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 900,000 |  | 1,400,000 |  |  |  |  |  |  |  |
AstraZeneca Termination Agreement | AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  |  |  |  |  | 1,000,000 |  | 100,000 |  |  |  |  | $ 11,600,000 |  |  |
Percentage of royalty revenue |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |
Percentage of non royalty revenue |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential payment per agreement |  |  |  |  | $ 75,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Fosun Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 0 |  | 0 |  |  |  |  |  |  |  |
Fosun Agreement | Fosun Pharma |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  | $ 12,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercialization milestones |  |  |  |  |  |  | $ 110,000,000 |  |  |  |  |  |  |  |  |  |
Threshold percentage of net sales for tiered royalties |  |  |  |  |  |  | 20.00% | 20.00% |  |  |  |  |  |  |  |  |
Knight Agreement | Knight |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 2,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercialization milestones |  |  |  |  |  |  | $ 17,400,000 | $ 22.2 |  |  |  |  |  |  |  |  |
Knight Agreement | Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 13,000 |  | 700,000 |  |  |  |  |  |  |  |
Knight Agreement | Product supply revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 0 |  | 100,000 |  |  |  |  |  |  |  |
XuanZhu Agreement | XuanZhu |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee recognized | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second milestone payment | $ 800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
XuanZhu Agreement | Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
ASU 2014-09 | Adjustments | 2017 KKC Agreement | Kyowa Kirin Co. Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unbilled revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000
ASU 2014-09 | Adjustments | 2017 KKC Agreement | AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Uncharged license fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000

X
- Definition The amount of initial transaction price. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsInitialTransactionPrice
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of licenses fee recognized during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsLicenseFee
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of second milestone payment recognized during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsSecondMilestonePayment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees, First Installment + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees, Second Installment + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Potential Commercialization Milestones + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of future development and commercialization milestone under collaborative arrangements. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Potential Development Milestones + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialDevelopmentMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of separate collaborative agreements. + References No definition available. + Details
Name: | ardx_NumberOfSeparateCollaborativeAgreements
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of non-royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfNonRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prepayment Received, Asset + References No definition available. + Details
Name: | ardx_PrepaymentReceivedAsset
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Term of agreement. + References No definition available. + Details
Name: | ardx_TermOfAgreement
Namespace Prefix: | ardx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of payment of first installment fee. + References No definition available. + Details
Name: | ardx_TermOfPaymentOfLicenseFeeFirstInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the threshold percentage of net sales for tiered royalties. + References No definition available. + Details
Name: | ardx_ThresholdPercentageOfSalesForTieredRoyalties
Namespace Prefix: | ardx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Unbilled Prepayment Assets + References No definition available. + Details
Name: | ardx_UnbilledPrepaymentAssets
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of uncharged license fee classified as current. + References No definition available. + Details
Name: | ardx_UnchargedLicenseFeeCurrent
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Uncharged License Fee Reclassified To Accounts Payable + References No definition available. + Details
Name: | ardx_UnchargedLicenseFeeReclassifiedToAccountsPayable
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 + Details
Name: | us-gaap_CostOfRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_AstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_XuanZhuAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_XuanzhuHKBiopharmaceuticalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |